Gastrointestinal stromal tumour in pregnancy

BMJ Case Reports

Volumn , Issue , 2011, Pages

  Stubbs, Benjamin Michael ^a   Desai, Ankit ^a   Singh, Seema ^b   Seddon, Beatrice ^a   Khan, Farrukh ^b  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b BASILDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; HEMOGLOBIN; IMATINIB; SMOOTH MUSCLE ACTIN; STEM CELL FACTOR RECEPTOR;

ABDOMINAL MASS; ADULT; ANEMIA; ARTICLE; CANCER RELAPSE; CASE REPORT; CESAREAN SECTION; CLINICAL DECISION MAKING; DIFFERENTIAL DIAGNOSIS; DIZZINESS; EARLY INTERVENTION; ECHOGRAPHY; FEMALE; FOLLOW UP; GASTROINTESTINAL BIOPSY; GASTROINTESTINAL STROMAL TUMOR; HEMICOLECTOMY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABORATORY DIAGNOSIS; LETHARGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PREGNANCY; PRIORITY JOURNAL; SMALL INTESTINE RESECTION; TREATMENT PLANNING; TUMOR LOCALIZATION;

EID: 80051754543     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr.01.2011.3737     Document Type: Article

References (18)

1. Nilsson B, Bümming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer 2005;103:821-829 (Pubitemid 40216412)
2. Tryggvason G, Gíslason HG, Magnússon MK, et al. Gastrointestinal stromal tumors in Iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratifi cation study. Int J Cancer 2005;117:289-293 (Pubitemid 41377450)
3. Goettsch WG, Bos SD, Breekveldt-Postma N, et al. Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer 2005;41:2868-2872 (Pubitemid 41713125)
4. Valente PT, Fine BA, Parra C, et al. Gastric stromal tumor with peritoneal nodules in pregnancy: tumor spread or rare variant of diffuse leiomyomatosis. Gynecol Oncol 1996;63:392-397 (Pubitemid 26409002)
5. Lanzafame S, Minutolo V, Caltabiano R, et al. About a case of GIST occurring during pregnancy with immunohistochemical expression of epidermal growth factor receptor and progesterone receptor. Pathol Res Pract 2006;202:119-123 (Pubitemid 43125713)
6. Scherjon S, Lam WF, Gelderblom H, et al. Gastrointestinal stromal tumor in pregnancy: a case report. Case Report Med 2009;2009:456402.
7. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006;23:70-83. (Pubitemid 44692418)
8. Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 1983;7:507-519 (Pubitemid 13021488)
9. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005;29:52-68. (Pubitemid 40023952)
10. Miettinen M, Makhlouf H, Sobin LH, et al. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 2006;30:477-489 (Pubitemid 43740149)
11. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002;33:459-465 (Pubitemid 34747864)
12. Demetri GD, Benjamin RS, Blanke CD, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)-update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 2007;5(Suppl 2):S1-29;quiz S30.
13. Copper RL, Goldenberg RL, Creasy RK, et al. A multicenter study of preterm birth weight and gestational age-specifi c neonatal mortality. Am J Obstet Gynecol 1993;168(1 Pt 1):78-84. (Pubitemid 23047616)
14. Van Glabbeke MM, Owzar K, Rankin C, et al. GIST Meta-analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): a metaanalysis based on 1,640 patients (pts). J Clin Oncol (Meeting Abstracts) 2007;25:10004.
15. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase ii trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008;26:620-625 (Pubitemid 351264357)
16. Eisenberg BL, Harris J, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 2009;99:42-47
17. Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:1097-1104
18. Gambacorti-Passerini CB, Tornaghi L, Marangon E, et al. Imatinib concentrations in human milk. Blood 2007;109:1790. (Pubitemid 46239616)